View Digital Edition
All eyes are on Washington this fall, as deliberations begin on recommendations from the congressional joint “super” committee. Congress and the president failed to achieve resolution regarding the debt ceiling this summer, and now this newly created 12-person committee will recommend at least $1.5 trillion in additional deficit reduction measures through 2021, by November 23, 2011.
With today’s focus on the National Committee for Quality Assurance’s Patient-Centered Medical Home (PCMH) as a viable option for healthcare delivery and cost reform, a group of researchers explored how best to translate the concept from the primary care model to oncology care. What they found is that an Oncology Medical Home (OMH) model may revolutionize cancer care and reimbursement (J Clin Oncol. 2011;29[suppl]:Abstract e16641).
As most of us know, poor previsit processes create havoc on a practice’s ability to post, bill, and collect for services¬†rendered (Petaschnick J. Health Care Collector. 2007;20:1,10-12).
Hospital-based cancer centers and service lines face tough competitive pressures from other practices and hospitals competing for market share, reputation, referrals, and managed care contracts. For hospital-based programs, competition also can arise internally, as other service lines and business units compete with oncology for investments and resources at a time when hospital margins are shrinking.
The deadline for going live with the International Classification of Diseases (ICD), 10th edition is October 1, 2013, and the Centers for Medicare & Medicaid Services repeatedly has attested this as a firm deadline with no extensions, delays, or grace periods.
Although members of the cancer care team will sacrifice their time and energy for the care of their patients, all too often it is done to the detriment of themselves and their families, especially in the areas of personal financial planning. This article focuses on protecting your most valuable asset —your ability to earn an income.
This has proven to be a difficult year for reimbursement for community cancer care providers. Al - though there are many hurdles to appropriate reimbursement, 3 issues are hanging fire in Congress this year. The sustainable growth rate (SGR) formula remains unfixed. Drug manufacturers’ promptpay discount is still calculated in the average sales price (ASP) for physician reimbursement. And most recently, select members of Congress are considering across-the-board cuts of up to 2% in Medicare reimbursement.
From informal discussions in 2004 to a ribbon cutting in 2008, Dana-Farber Cancer Institute (DFCI) and New Ham pshire Oncology-Hematology (NHOH) embarked on an odyssey to provide world-class cancer care in Londonderry, New Hampshire (Sidebar), according to Denis B. Hammond, MD, chief medical oncologist at NHOH, who detailed “why and how” a multisite, single-specialty adult hematology and oncology independent practice affiliated with an academic cancer center at the 2011 annual meeting of the American Society of Clinical Oncology.
It is no secret federal auditors promise to assail providers through a variety of strong recoupment initiatives. Evaluation and management (E/M) services are primed for this offensive.
To maintain pace with the ongoing IT revolution, practices must find cost-effective solutions for purchasing and implementing electronic technologies. There a number of funding options available to finance investments in technology. These investments may include consulting, hardware, software, and training. It may be helpful to speak with other practices in your area to learn from their experiences.

Results 1 - 10 of 10
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management